Wells Fargo Adjusts Price Target on Henry Schein to $75 From $80, Maintains Equalweight Rating
Henry Schein Price Target Cut to $86.00/Share From $90.00 by Barrington Research
Henry Schein Analyst Ratings
Henry Schein Positioned for Growth: Buy Rating Reaffirmed Amid Strategic Expansion and Board Expertise
Evercore Maintains Henry Schein(HSIC.US) With Hold Rating, Cuts Target Price to $68
William Blair Maintains Henry Schein(HSIC.US) With Hold Rating
Research Alert: Hsic: Mixed Sales Trends In Dental, Medical, Q1 Eps Tops Estimates
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and Axsome Therapeutics (AXSM)
Piper Sandler Maintains Henry Schein(HSIC.US) With Buy Rating, Cuts Target Price to $77
Henry Schein Analyst Ratings
Piper Sandler Maintains Overweight on Henry Schein, Lowers Price Target to $77
BofA Securities Maintains Henry Schein(HSIC.US) With Buy Rating, Cuts Target Price to $85
Morgan Stanley Maintains Henry Schein(HSIC.US) With Sell Rating, Maintains Target Price $55
Morgan Stanley Keeps Their Sell Rating on Henry Schein (HSIC)
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and CSL (OtherCMXHF)
Mizuho Securities Maintains Henry Schein(HSIC.US) With Hold Rating, Announces Target Price $76
Mizuho Adjusts Price Target on Henry Schein to $76 From $78, Maintains Neutral Rating
William Blair Maintains Henry Schein(HSIC.US) With Hold Rating
Cautious Hold Rating on Henry Schein Amid New Segment Disclosures and Strategic Initiatives
Piper Sandler Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $83